You searched for "PCa"
Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study
This study examined a cohort of non-statin using patients who participated in the REDUCE study. The REDUCE study included men who had an elevated prostate specific antigen (PSA) and a negative baseline prostate biopsy who then underwent year two and...Demanding cases or nightmares in uro-oncology? Jan/Feb 2023
6 January 2023
| Jonathan Noël, Ata Jaffer, Ben Challacombe
|
URO - Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...
Prostate cancer: Black men more likely to be diagnosed at later stages
9 January 2025
|
Charities, Research & Development
Latest data shows Black men have higher rates of stage 3 or stage 4 prostate cancer diagnoses compared with white men. Black men diagnosed at a later stage in their 60s are 14% less likely to get NICE approved treatment...
Rotterdam Prostate Cancer Risk app
The widespread use of prostate specific antigen (PSA) testing has led to diagnostic difficulties for patients and urologists. The sensitivity and specificity characteristics of PSA are far from optimal. To try and improve the predictive accuracy of PSA measurements, nomograms...Updated guide on integrated paediatric continence services to significantly improve children’s lives and save NHS cost
The Paediatric Continence Forum has recently launched its updated Guide on how to commission and run integrated, nurse-led, community-based paediatric bladder and bowel (continence) services. These are clinically effective, improve the lives of children and their families and generate significant...
Factors and time to conversion from prostate cancer active surveillance to treatment
5 January 2022
| Jay Khastgir
|
URO - Urologic Oncology
Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy
1 September 2014
| Sophia Cashman
|
URO - Urologic Oncology
Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...
Rishi Sunak joins Prostate Cancer Research as an ambassador
26 February 2025
|
Charities, Research & Development
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...
Prostate cancer
1 July 2015
| David Mak, Nick Rukin
|
URO - Urologic Oncology
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...
Performance status may alter outcomes in those treated with abiraterone
1 May 2015
| Sophia Cashman
|
URO - Urologic Oncology
The drug therapies available for those with metastatic castrate-resistant prostate cancer have increased over the past few years. Abiraterone, a CYP17 inhibitor, has been proven effective in phase three trials, however those with poor performance status were largely under-represented in...
ASAP: is a repeat biopsy necessary?
1 May 2016
| Pravisha Ravindra
|
URO - Urologic Oncology
This study examined the validity of current US and European guidelines on the management of patients diagnosed with atypical small acinar proliferation (ASAP). Current guidance states that these patients should undergo repeat biopsy within three to six months due to...
Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel
1 September 2015
| Pravisha Ravindra
|
URO - Urologic Oncology
This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...
